Gouty Arthritis (Gout) – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Gouty Arthritis (Gout) – Pipeline Review, H2 2020’, provides an overview of the Gouty Arthritis (Gout) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout)

– The report reviews pipeline therapeutics for Gouty Arthritis (Gout) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Gouty Arthritis (Gout) therapeutics and enlists all their major and minor projects

– The report assesses Gouty Arthritis (Gout) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Gouty Arthritis (Gout)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acquist Therapeutics

Aequus BioPharma Inc

Allena Pharmaceuticals Inc

Arthrosi Therapeutics Inc

C&C Research Laboratories

DevaCell Inc

Dianomi Therapeutics Inc

Dyve Biosciences Inc

Enzychem Lifesciences Corp

Fochon Pharmaceutical Ltd

FortuneRock (China) Ltd

Fuji Yakuhin Co Ltd

General Genomics Llc

General Regeneratives Shanghai Ltd

GeneScience Pharmaceuticals Co Ltd

Hinova Pharmaceuticals Inc

Horizon Therapeutics Plc

InflammatoRx inc

InventisBio Inc

Jiangsu Atom Bioscience and Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

LG Chem Ltd

Nippon Chemiphar Co Ltd

Novartis AG

Olatec Therapeutics LLC

Opsona Therapeutics Ltd

PegBio Co Ltd

Polaris Pharmaceuticals Inc

Protalix BioTherapeutics Inc

R Pharm

Rigel Pharmaceuticals Inc

Shanghai Yingli Pharmaceutical Co Ltd

Shanton Pharma Co Ltd

Swedish Orphan Biovitrum AB

TaiwanJ Pharmaceuticals Co Ltd

Teijin Pharma Ltd

TWi Biotechnology Inc

Wellstat Therapeutics Corp

XL-protein GmbH

Table of Contents

Table of Contents

Introduction

Gouty Arthritis- Overview

Gouty Arthritis- Therapeutics Development

Gouty Arthritis- Therapeutics Assessment

Gouty Arthritis- Companies Involved in Therapeutics Development

Gouty Arthritis- Drug Profiles

Gouty Arthritis- Dormant Projects

Gouty Arthritis- Discontinued Products

Gouty Arthritis- Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Gouty Arthritis (Gout), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Products under Development by Companies, H2 2020 (Contd..2), H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Gouty Arthritis (Gout) – Pipeline by Acquist Therapeutics, H2 2020

Gouty Arthritis (Gout) – Pipeline by Aequus BioPharma Inc, H2 2020

Gouty Arthritis (Gout) – Pipeline by Allena Pharmaceuticals Inc, H2 2020

Gouty Arthritis (Gout) – Pipeline by Arthrosi Therapeutics Inc, H2 2020

Gouty Arthritis (Gout) – Pipeline by C&C Research Laboratories, H2 2020

Gouty Arthritis (Gout) – Pipeline by DevaCell Inc, H2 2020

Gouty Arthritis (Gout) – Pipeline by Dianomi Therapeutics Inc, H2 2020

Gouty Arthritis (Gout) – Pipeline by Dyve Biosciences Inc, H2 2020

Gouty Arthritis (Gout) – Pipeline by Enzychem Lifesciences Corp, H2 2020

Gouty Arthritis (Gout) – Pipeline by Fochon Pharmaceutical Ltd, H2 2020

Gouty Arthritis (Gout) – Pipeline by FortuneRock (China) Ltd, H2 2020

Gouty Arthritis (Gout) – Pipeline by Fuji Yakuhin Co Ltd, H2 2020

Gouty Arthritis (Gout) – Pipeline by General Genomics Llc, H2 2020

Gouty Arthritis (Gout) – Pipeline by General Regeneratives Shanghai Ltd, H2 2020

Gouty Arthritis (Gout) – Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2020

Gouty Arthritis (Gout) – Pipeline by Hinova Pharmaceuticals Inc, H2 2020

Gouty Arthritis (Gout) – Pipeline by Horizon Therapeutics Plc, H2 2020

Gouty Arthritis (Gout) – Pipeline by InflammatoRx inc, H2 2020

Gouty Arthritis (Gout) – Pipeline by InventisBio Inc, H2 2020

Gouty Arthritis (Gout) – Pipeline by Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, H2 2020

Gouty Arthritis (Gout) – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2020

Gouty Arthritis (Gout) – Pipeline by LG Chem Ltd, H2 2020

Gouty Arthritis (Gout) – Pipeline by Nippon Chemiphar Co Ltd, H2 2020

Gouty Arthritis (Gout) – Pipeline by Novartis AG, H2 2020

Gouty Arthritis (Gout) – Pipeline by Olatec Therapeutics LLC, H2 2020

Gouty Arthritis (Gout) – Pipeline by Opsona Therapeutics Ltd, H2 2020

Gouty Arthritis (Gout) – Pipeline by PegBio Co Ltd, H2 2020

Gouty Arthritis (Gout) – Pipeline by Polaris Pharmaceuticals Inc, H2 2020

Gouty Arthritis (Gout) – Pipeline by Protalix BioTherapeutics Inc, H2 2020

Gouty Arthritis (Gout) – Pipeline by R Pharm, H2 2020

Gouty Arthritis (Gout) – Pipeline by Rigel Pharmaceuticals Inc, H2 2020

Gouty Arthritis (Gout) – Pipeline by Shanghai Yingli Pharmaceutical Co Ltd, H2 2020

Gouty Arthritis (Gout) – Pipeline by Shanton Pharma Co Ltd, H2 2020

Gouty Arthritis (Gout) – Pipeline by Swedish Orphan Biovitrum AB, H2 2020

Gouty Arthritis (Gout) – Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2020

Gouty Arthritis (Gout) – Pipeline by Teijin Pharma Ltd, H2 2020

Gouty Arthritis (Gout) – Pipeline by TWi Biotechnology Inc, H2 2020

Gouty Arthritis (Gout) – Pipeline by Wellstat Therapeutics Corp, H2 2020

Gouty Arthritis (Gout) – Pipeline by XL-protein GmbH, H2 2020

Gouty Arthritis (Gout) – Dormant Projects, H2 2020

Gouty Arthritis (Gout) – Dormant Projects, H2 2020 (Contd..1), H2 2020

Gouty Arthritis (Gout) – Dormant Projects, H2 2020 (Contd..2), H2 2020

Gouty Arthritis (Gout) – Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development for Gouty Arthritis (Gout), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports